JPWO2020198662A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020198662A5
JPWO2020198662A5 JP2021558521A JP2021558521A JPWO2020198662A5 JP WO2020198662 A5 JPWO2020198662 A5 JP WO2020198662A5 JP 2021558521 A JP2021558521 A JP 2021558521A JP 2021558521 A JP2021558521 A JP 2021558521A JP WO2020198662 A5 JPWO2020198662 A5 JP WO2020198662A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chimeric protein
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558521A
Other languages
English (en)
Japanese (ja)
Other versions
JP7773371B2 (ja
JP2022530742A5 (https=
JP2022530742A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025423 external-priority patent/WO2020198662A1/en
Publication of JP2022530742A publication Critical patent/JP2022530742A/ja
Publication of JP2022530742A5 publication Critical patent/JP2022530742A5/ja
Publication of JPWO2020198662A5 publication Critical patent/JPWO2020198662A5/ja
Priority to JP2025076699A priority Critical patent/JP2025118769A/ja
Application granted granted Critical
Publication of JP7773371B2 publication Critical patent/JP7773371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558521A 2019-03-28 2020-03-27 Clec9aベースキメラタンパク質複合体 Active JP7773371B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076699A JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962825584P 2019-03-28 2019-03-28
US62/825,584 2019-03-28
US201962906442P 2019-09-26 2019-09-26
US62/906,442 2019-09-26
PCT/US2020/025423 WO2020198662A1 (en) 2019-03-28 2020-03-27 Clec9a-based chimeric protein complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076699A Division JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Publications (4)

Publication Number Publication Date
JP2022530742A JP2022530742A (ja) 2022-07-01
JP2022530742A5 JP2022530742A5 (https=) 2023-03-31
JPWO2020198662A5 true JPWO2020198662A5 (https=) 2023-03-31
JP7773371B2 JP7773371B2 (ja) 2025-11-19

Family

ID=72609002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558521A Active JP7773371B2 (ja) 2019-03-28 2020-03-27 Clec9aベースキメラタンパク質複合体
JP2025076699A Pending JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076699A Pending JP2025118769A (ja) 2019-03-28 2025-05-02 Clec9aベースキメラタンパク質複合体

Country Status (8)

Country Link
US (2) US12351614B2 (https=)
EP (1) EP3947429A4 (https=)
JP (2) JP7773371B2 (https=)
KR (1) KR20220012227A (https=)
CN (2) CN120590542A (https=)
AU (1) AU2020244880A1 (https=)
CA (1) CA3133831A1 (https=)
WO (1) WO2020198662A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120590542A (zh) * 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
CA3133648A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
EP4225795A4 (en) * 2020-10-05 2025-03-26 Monash University Clec9a antibodies
CN121443629A (zh) * 2023-06-09 2026-01-30 奥里尼斯生物科学有限公司 基于clec9a的嵌合蛋白制剂

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055445T3 (es) 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2008014612A1 (en) 2006-08-02 2008-02-07 Mcgill University Fusion proteins and methods for modulation of immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
JP2012521199A (ja) 2009-03-23 2012-09-13 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 免疫応答を調節するための化合物および方法
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
US20130115189A1 (en) 2009-09-10 2013-05-09 Cytos Biotechnology Ag Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes
RU2577299C2 (ru) 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104245734B (zh) 2012-01-20 2017-09-05 非营利性组织佛兰芒综合大学生物技术研究所 靶向突变体α‑螺旋束细胞因子
ES2800426T3 (es) 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
EP2872158A1 (en) 2012-05-01 2015-05-20 The University of Sydney Vaccine and uses thereof
EP2882775B1 (en) * 2012-08-09 2018-02-14 Roche Glycart AG Asgpr antibodies and uses thereof
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
US20160145325A1 (en) 2013-04-29 2016-05-26 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
WO2015007536A2 (en) 2013-07-18 2015-01-22 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
CA2918119C (en) 2013-07-19 2022-11-29 Centre Hospitalier Regional Universitaire De Montpellier Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾tnfファミリーメンバー
DK3022226T3 (en) 2013-07-19 2019-03-25 Vib Vzw TARGETED MODIFIED IL-1 FAMILY MEMBERS
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
EP3580230B1 (en) 2017-02-07 2026-04-22 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Pd-1およびpd-l1結合物質
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ,インコーポレイテッド 線維芽細胞結合物質およびその使用
US20210024631A1 (en) 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CN120590542A (zh) * 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物

Similar Documents

Publication Publication Date Title
JP2024153643A5 (https=)
JP2021007390A5 (https=)
JP2023123649A5 (https=)
JP2022058385A5 (https=)
JP2021522175A5 (https=)
CN103965363B (zh) 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
JP2020530296A5 (https=)
RS55609B1 (sr) Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
JP2013534812A (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
JP2021505156A5 (https=)
JPWO2019204592A5 (https=)
JPWO2021189139A5 (https=)
JP2023076596A5 (https=)
JP2021518132A5 (https=)
JPWO2021116182A5 (https=)
JP2022530742A (ja) Clec9aベースキメラタンパク質複合体
JPWO2022094299A5 (https=)
JPWO2020198662A5 (https=)
JP2018516247A5 (https=)
IL310164A (en) Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
JPWO2020191342A5 (https=)
JP2019518713A5 (https=)
JPWO2022129560A5 (https=)
CN101210048A (zh) 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途
WO2024017281A1 (zh) 多特异性抗体及其用途